Aligos Therapeutics (ALGS) announced positive data from eight presentations at the European Association for the Study of the Liver, EASL, Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. In HBeAg+ subjects with a very high mean HBV DNA level of 8.0 log10 IU/mL at baseline, all experienced profound and persistent HBV DNA reductions after receiving an oral daily dose of 300 mg ALG-000184 monotherapy. At Week 48, 6 of 10 subjects achieved HBV DNA less than LLOQ . With treatment extension, this rate increased to 9 of 9 subjects at Week 96. Additionally, HBV DNA level continuously declined to less than LLOQ in 5 of 9 subjects at Week 96. In HBeAg- subjects, all 11 had rapid decline in HBV DNA levels and achieved sustained HBV DNA suppression by Week 24. The HBV DNA suppression level was maintained in the ALG-000184 monotherapy cohort for up to 96 weeks, with further decline in HBV DNA to less than LLOQ, target not detected, observed in all subjects at Week 96.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics Reports Strong Q1 2025 Progress
- Aligos Therapeutics reports Q1 EPS ($2.11), consensus ($3.15)
- UPS downgraded, ServiceNow upgraded: Wall Street’s top analyst calls
- Aligos Therapeutics initiated with a Buy at Lucid Capital
- Promising Clinical Data and Strategic Milestones Drive Buy Rating for Aligos Therapeutics